Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Decides to Establish Genomics Center After Failing to Find Partner

Premium

BASEL, Switzerland--The decision by Novartis to invest $250 million to build a genomics research center in California (see BioInform, April 13) came after several failed attempts to find a partner.

Paul Herrling, head of basic research, said that when Novartis looked at companies active in the genomics field, "We saw that they all were specialized in one or the other technology--bioinformatics, mouse transgenes, worm, proteomics--but none were integrated, none had available all of these techniques. We firmly believe that in order to solve gene function it is important to have all of these techniques available in one place."

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.